| 名称 | Pramipexole dihydrochloride hydrate |
| 描述 | Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain. |
| 体外活性 | Pramipexole (4-100 mM) significantly attenuated DA- or L-DOPA-induced cytotoxicity and apoptosis, an effect that was not inhibited by the D3 receptor antagonist, U-99194 A, or the D2 receptor antagonist, raclopride.Pramipexole also protected MES23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. cytotoxicity.Pramipexole effectively inhibited melanin formation.Pramipexole was neuroprotective against nigrostriatal dopamine neurons in hypoxic-ischemic and methamphetamine models. When incubated with SH-SY5Y cells and perfused into rat striatum, Pramipexole reduced the level of oxygen radicals produced by methylpyridinium ion (MPP+).Pramipexole also concentration-dependently inhibited the opening of mitochondrial transporter pore induced by calcium, phosphate, or MPP+. Pramipexole dose Pramipexole dose-dependently decreased dopamine metabolite levels, while striatal dopamine levels remained unchanged. |
| 体内活性 | Pramipexole (4-100 mM) significantly attenuated DA- or L-DOPA-induced cytotoxicity and apoptosis, an effect that was not inhibited by the D3 receptor antagonist, U-99194 A, or the D2 receptor antagonist, raclopride.Pramipexole also protected MES23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. cytotoxicity.Pramipexole effectively inhibited melanin formation.Pramipexole was neuroprotective against nigrostriatal dopamine neurons in hypoxic-ischemic and methamphetamine models. When incubated with SH-SY5Y cells and perfused into rat striatum, Pramipexole reduced the level of oxygen radicals produced by methylpyridinium ion (MPP+).Pramipexole also concentration-dependently inhibited the opening of mitochondrial transporter pore induced by calcium, phosphate, or MPP+. Pramipexole dose Pramipexole dose-dependently decreased dopamine metabolite levels, while striatal dopamine levels remained unchanged. |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 3.46 mg/mL (11.45 mM), Sonication is recommended.
H2O : 55 mg/mL (182 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| 关键字 | transient | Pramipexole dihydrochloride | Pramipexole dihydrochloride hydrate | syndrome | disease | Pramipexole dihydrochloride Hydrate | RLS | neurological | Dopamine Receptor | Parkinson's | cerebral | middle | Inhibitor | artery | legs | occlusion | inhibit | Pramipexole 2HCl | restless | tMCAO | neuroprotection | recovery |
| 相关产品 | Olanzapine | CLOZAPINE N-OXIDE | Mirtazapine | Octopamine hydrochloride | Octodrine | Citicoline | Phenothiazine | Oxolinic acid | Mianserin hydrochloride | Doxepin hydrochloride |
| 相关库 | 神经退行性疾病化合物库 | 膜蛋白靶向化合物库 | EMA 上市药物库 | 抗癌临床化合物库 | 药物功能重定位化合物库 | FDA 上市药物库 | 抗癌上市药物库 | 已知活性化合物库 | GPCR靶点分子库 | 抗癌药物库 |
United States
